Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article

  • Post published:March 22, 2023
  • Post category:Press Release
Read more about the article CORRECTION — BetterLife Closes $1,857,143 of Private Placement

CORRECTION — BetterLife Closes $1,857,143 of Private Placement

  • Post published:March 14, 2023
  • Post category:Press Release
Read more about the article BetterLife Closes $1,857,143 of Private Placement

BetterLife Closes $1,857,143 of Private Placement

  • Post published:March 14, 2023
  • Post category:Press Release
Read more about the article BetterLife Files Amended and Restated Offering Document for Offering of Units

BetterLife Files Amended and Restated Offering Document for Offering of Units

  • Post published:March 11, 2023
  • Post category:Press Release
Read more about the article Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”

Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”

  • Post published:March 9, 2023
  • Post category:Press Release
Read more about the article BetterLife Announces Pricing of Proposed Offering of Units

BetterLife Announces Pricing of Proposed Offering of Units

  • Post published:March 8, 2023
  • Post category:Press Release
Read more about the article BetterLife Announces Offering of Units

BetterLife Announces Offering of Units

  • Post published:March 8, 2023
  • Post category:Press Release
Read more about the article BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

  • Post published:January 27, 2023
  • Post category:Press Release
Read more about the article BetterLife Announces Closing of Private Placement

BetterLife Announces Closing of Private Placement

  • Post published:December 7, 2022
  • Post category:Press Release
Read more about the article BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

  • Post published:September 27, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More